MD Antonio P. Palumbo

Publikovaná abstrakta

• A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM)
• A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens
• A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients
• A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients
• A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis
• Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
• Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years Follow-up and Extensive Subsequent Therapy Use
• Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): Results from a phase 3 study (FOCUS)
• Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
• CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSIONFREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
• Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
• Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
• Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients
• Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients
• Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies...
• CONTINUOUS LENALIDOMIDE TREATMENT FOR TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATE ON PATIENTS AGED 65-75 YEARS ENROLLED IN MM-015
• Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).
• Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study
• DROPLET DIGITAL PCR (DDPCR) AND REAL-TIME PCR (RQ-PCR): A HEAD TO HEAD COMPARISON FOR MRD DETECTION IN MYELOMA (MM) MANTLE CELL LYMPHOMA (MCL) AND FOLLICULAR LYMPHOMA (FL)
• EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
• EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS
• Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
• Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
• EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL
• Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)
• Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
• Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
• ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
• ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
• GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
• Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
• IMPACT OF CONTINUOUS TREATMENT VS FIXED DURATION OF THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS: PFS1, PFS2, OS ENDPOINTS
• Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
• Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)
• IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS
• Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM
• IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL
• Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older
• Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
• Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.
• LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOLLOWED BY LENALIDOMIDE MAINTENANCE PROVIDES FAVOURABLE EFFICACY AND HEALTH-RELATED QUALITY-OF-LIFE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ≥65 YEARS
• LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS
• MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL
• Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years
• Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression
• MMY-3002: A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
• REVISED-INTERNATIONAL STAGING SYSTEM (R-ISS): A NEW AND SIMPLE PROGNOSTIC ASSESSMENT FOR MULTIPLE MYELOMA.
• SAFETY PROFILE AND MANAGEMENT IN MM-015 COMPARING LENALIDOMIDE-MELPHALAN-PREDNISONE FOLLOWED BY LENALIDOMIDE MAINTENANCE (MPR-R) WITH MP AND MPR IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
• SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE: A META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA
• Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD)
• Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
• Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
• The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy
• Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
• VANTAGE 088: FINAL RESULTS FROM THE GLOBAL PHASE 3 TRIAL OF THE MULTI-HISTONE DEACETYLASE INHIBITOR VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
• Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial